(Q40999403)

25 September 2017

1 reference

title

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. (English)

1 reference

25 September 2017

2

Gee JM

1 reference

25 September 2017

Nicholson RI

1

1 reference

25 September 2017

Bryant S

3

1 reference

25 September 2017

Francis AB

4

1 reference

25 September 2017

McClelland RA

5

1 reference

25 September 2017

Knowlden J

6

1 reference

25 September 2017

Wakeling AE

7

1 reference

25 September 2017

Osborne CK

8

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 April 1996

1 reference

Annals of the New York Academy of Sciences

25 September 2017

1 reference

25 September 2017

784

1 reference

25 September 2017

325-335

1 reference

The future of new pure antiestrogens in clinical breast cancer

25 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Dopaminergic and Ligand-Independent Activation of Steroid Hormone Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Hormone resistance, invasiveness, and metastatic potential in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1996.TB16247.X

10.1111/J.1749-6632.1996.TB16247.X

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference